Detailed information for compound 309646
Basic information
Technical information
- Name: Unnamed compound
- MW: 604.498 | Formula: C21H27IN4O5S2
-
H donors: 3
H acceptors: 5
LogP: 1.16
Rotable bonds: 15
Rule of 5 violations (Lipinski): 2 - SMILES: SC[C@@H](C(=O)SC1CC(=O)N(C1=O)CCCCCNC(=O)CNC(=O)c1cccc(c1)[125I])N
- InChi: 1S/C21H27IN4O5S2/c22-14-6-4-5-13(9-14)19(29)25-11-17(27)24-7-2-1-3-8-26-18(28)10-16(20(26)30)33-21(31)15(23)12-32/h4-6,9,15-16,32H,1-3,7-8,10-12,23H2,(H,24,27)(H,25,29)/t15-,16?/m0/s1/i22-2
- InChiKey: DTWJXEDGRFCWAL-PZMDIYBFSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
No curated genes were found associated with this compound
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.035 | 1 | 0.5 |
| Brugia malayi | Fibulin-1 precursor | 0.0047 | 0.0346 | 0.0346 |
| Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.035 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.035 | 1 | 1 |
| Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0047 | 0.0346 | 0.0346 |
| Treponema pallidum | ATP-dependent RNA helicase | 0.035 | 1 | 0.5 |
| Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.035 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0132 | 0.3048 | 0.3048 |
| Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.035 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.0197 | 0.0197 |
| Echinococcus multilocularis | laminin | 0.0047 | 0.0346 | 0.0153 |
| Onchocerca volvulus | 0.0167 | 0.4189 | 0.3107 | |
| Brugia malayi | Low-density lipoprotein receptor-related protein, putative | 0.0043 | 0.0232 | 0.0232 |
| Echinococcus granulosus | eukaryotic initiation factor 4A | 0.035 | 1 | 1 |
| Brugia malayi | Calcium binding EGF domain containing protein | 0.0047 | 0.0346 | 0.0346 |
| Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.035 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0059 | 0.0729 | 0.0729 |
| Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.035 | 1 | 1 |
| Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.035 | 1 | 0.5 |
| Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.035 | 1 | 1 |
| Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.035 | 1 | 0.5 |
| Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0042 | 0.0197 | 0.0197 |
| Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0085 | 0.157 | 0.157 |
| Plasmodium falciparum | eukaryotic initiation factor 4A | 0.035 | 1 | 0.5 |
| Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.035 | 1 | 0.5 |
| Plasmodium vivax | RNA helicase-1, putative | 0.035 | 1 | 0.5 |
| Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.035 | 1 | 1 |
| Brugia malayi | Calcium binding EGF domain containing protein | 0.0167 | 0.4189 | 0.4189 |
| Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.035 | 1 | 1 |
| Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.035 | 1 | 0.5 |
| Loa Loa (eye worm) | calcium binding EGF domain-containing protein | 0.0167 | 0.4189 | 0.4189 |
| Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.035 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.0382 | 0.0382 |
| Echinococcus granulosus | laminin | 0.0047 | 0.0346 | 0.0153 |
| Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.035 | 1 | 1 |
| Echinococcus multilocularis | fibrillin 1 | 0.0047 | 0.0346 | 0.0153 |
| Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0085 | 0.157 | 0.157 |
| Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.0197 | 0.0197 |
| Leishmania major | eukaryotic initiation factor 4a, putative | 0.035 | 1 | 0.5 |
| Leishmania major | eukaryotic initiation factor 4a, putative | 0.035 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.0197 | 0.0197 |
| Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.035 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.009 | 0.172 | 0.172 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Radioactivity (ADMET) | = 0.04 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.04 % | Cumulative radioactivity exerted by compound in the urine at 24 hour postinjection of [131 I ]L-HML-NGA and compound | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.04 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.06 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.06 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.06 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.06 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.07 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neckafter 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.07 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neckafter 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.23 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.23 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.24 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.24 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.32 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.32 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.38 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.38 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.46 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.46 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.54 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.54 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.61 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and [compound in mice. It is expressed as percent injected dose per stomach after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.61 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and [compound in mice. It is expressed as percent injected dose per stomach after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.64 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.64 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.68 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.68 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.71 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.71 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.76 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.76 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per gram of blood tissue after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.77 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.77 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.8 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 0.8 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 1.48 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 1.48 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per stomach after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 1.62 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 1.62 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 1.72 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 1.72 % | The biodistribution time for compound radioactivity after concomitant administration of [[131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per kidney after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 5.72 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 5.72 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 7.17 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 7.17 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 10.12 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 10.12 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 25.46 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 25.46 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per neck after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 33.84 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 33.84 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 34.19 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 34.19 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 30 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 55.62 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestineafter 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 55.62 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestineafter 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 58.83 % | Cumulative radioactivity exerted by compound in the feces at 24 hour postinjection of [131 I ]L-HML-NGA and compound. | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 59.36 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 59.36 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per intestine after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 77.12 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 77.12 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 15 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 93.75 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 93.7500000000004 % | The biodistribution time for compound radioactivity after concomitant administration of [131 I ]L-HML-NGA and compound in mice. It is expressed as percent injected dose per liver after 5 minutes | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 97.26 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 24 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 97.26 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 24 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 98.56 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 6 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 98.5600000000002 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 6 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 99.12 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 99.1200000000001 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 3 hours | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 100.07 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 1 hour | ChEMBL. | 9258371 |
| Radioactivity (ADMET) | = 100.07 % | The percent protein-bound radioactivity in NGAfractions following incubation of radioidinated compound in human serum after 1 hour | ChEMBL. | 9258371 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL173732
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.